Login Register Cart 0
Generic placeholder image

Current Drug Research Reviews

Editor-in-Chief

ISSN (Print): 2589-9775
ISSN (Online): 2589-9783

Back
Journal Home About Journal Editorial Board Current Issue Volumes/Issues
Subscribe
Perspective

Neuroinflammation, Diabetes and COVID-19: Perspectives Coming from Ca2+/cAMP Signalling

Author(s): Leandro Bueno Bergantin*

Volume 14, Issue 1, 2022

Published on: 21 January, 2022

Page: [6 - 10] Pages: 5

DOI: 10.2174/2589977514666211231141401

Abstract

A link between inflammatory diseases, e.g., epilepsy, dementia, diabetes, and COVID-19, has been established. For instance, observational studies involving several individuals reported that people with epilepsy show an enhanced incidence of manifesting dysfunctions related to cognition, e.g., dementia, while people with dementia have a higher incidence of manifesting epilepsy, thus an evident bidirectional relationship between epilepsy and dementia might occur. In addition, epilepsy commonly cooccurs in patients with diabetes, indicating an association between these two disorders. Intriguingly, some reports have also observed a poor prognosis of people with both diabetes and COVID-19. It is recognized that a dyshomeostasis of both Ca2+ and cAMP signalling pathways could be a molecular connection for these disorders. Therefore, clarifying this clinical relationship among epilepsy, dementia, diabetes, and COVID-19 may outcome in novel hypotheses for identifying the etiology of these disorders.

Keywords: Epilepsy, diabetes, dementia, Ca2+/CAMP signalling, Ca2+ channel blockers, pharmacotherapy, neurodegeneration, COVID-19.

« Previous Next »
Graphical Abstract

[1]
Pandis D, Scarmeas N. Seizures in Alzheimer disease: clinical and epidemiological data. Epilepsy Curr 2012; 12(5): 184-7.
[http://dx.doi.org/10.5698/1535-7511-12.5.184] [PMID: 23118603]
[2]
Yun C, Xuefeng W. Association between seizures and diabetes mellitus: a comprehensive review of literature. Curr Diabetes Rev 2013; 9(4): 350-4.
[http://dx.doi.org/10.2174/15733998113099990060] [PMID: 23590576]
[3]
Abdi A, Jalilian M, Sarbarzeh PA, Vlaisavljevic Z. Diabetes and COVID-19: A systematic review on the current evidences. Diabetes Res Clin Pract 2020; 166: 108347.
[http://dx.doi.org/10.1016/j.diabres.2020.108347] [PMID: 32711003]
[4]
Tsalamandris S, Antonopoulos AS, Oikonomou E, et al. The role of inflammation in diabetes: current concepts and future perspectives. Eur Cardiol 2019; 14(1): 50-9.
[http://dx.doi.org/10.15420/ecr.2018.33.1] [PMID: 31131037]
[5]
Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 1993; 259(5091): 87-91.
[http://dx.doi.org/10.1126/science.7678183] [PMID: 7678183]
[6]
Ogston D, McAndrew GM. Fibrinolysis in obesity. Lancet 1964; 2(7371): 1205-7.
[http://dx.doi.org/10.1016/S0140-6736(64)91042-6] [PMID: 14215560]
[7]
Kaptoge S, Di Angelantonio E, Lowe G, et al. Emerging Risk Factors Collaboration. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet 2010; 375(9709): 132-40.
[http://dx.doi.org/10.1016/S0140-6736(09)61717-7] [PMID: 20031199]
[8]
Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997; 336(14): 973-9.
[http://dx.doi.org/10.1056/NEJM199704033361401] [PMID: 9077376]
[9]
Duncan BB, Schmidt MI, Pankow JS, et al. Low-grade systemic inflammation and the development of type 2 diabetes: the atherosclerosis risk in communities study. Diabetes 2003; 52(7): 1799-805.
[http://dx.doi.org/10.2337/diabetes.52.7.1799] [PMID: 12829649]
[10]
Kinney JW, Bemiller SM, Murtishaw AS, Leisgang AM, Salazar AM, Lamb BT. Inflammation as a central mechanism in Alzheimer’s disease. Alzheimers Dement (N Y) 2018; 4: 575-90.
[http://dx.doi.org/10.1016/j.trci.2018.06.014] [PMID: 30406177]
[11]
Vezzani A, Granata T. Brain inflammation in epilepsy: experimental and clinical evidence. Epilepsia 2005; 46(11): 1724-43.
[http://dx.doi.org/10.1111/j.1528-1167.2005.00298.x] [PMID: 16302852]
[12]
Lim S, Bae JH, Kwon HS, Nauck MA. COVID-19 and diabetes mellitus: from pathophysiology to clinical management. Nat Rev Endocrinol 2021; 17(1): 11-30.
[http://dx.doi.org/10.1038/s41574-020-00435-4] [PMID: 33188364]
[13]
Bergantin LB. Debating the “bidirectional link” between diabetes and depression through the Ca2+/cAMP signalling: Off-label effects of Ca2+ channel blockers. Pharmacol Res 2019; 141: 298-302.
[http://dx.doi.org/10.1016/j.phrs.2019.01.008] [PMID: 30639385]
[14]
Martin RC, Griffith HR, Faught E, Gilliam F, Mackey M, Vogtle L. Cognitive functioning in community dwelling older adults with chronic partial epilepsy. Epilepsia 2005; 46(2): 298-303.
[http://dx.doi.org/10.1111/j.0013-9580.2005.02104.x] [PMID: 15679511]
[15]
Piazzini A, Canevini MP, Turner K, Chifari R, Canger R. Elderly people and epilepsy: cognitive function. Epilepsia 2006; 47(Suppl. 5): 82-4.
[http://dx.doi.org/10.1111/j.1528-1167.2006.00884.x] [PMID: 17239113]
[16]
Schober E, Otto KP, Dost A, Jorch N, Holl R. German/Austrian DPV Initiative and the BMBF Competence Network Diabetes. Association of epilepsy and type 1 diabetes mellitus in children and adolescents: is there an increased risk for diabetic ketoacidosis? J Pediatr 2012; 160(4): 662-666.e1.
[http://dx.doi.org/10.1016/j.jpeds.2011.09.054] [PMID: 22056281]
[17]
Gowers W. Epilepsy and other chronic convulsive diseases: their causes, symptoms, & treatment. London: Churchill 1881.
[18]
Höller Y, Trinka E. What do temporal lobe epilepsy and progressive mild cognitive impairment have in common? Front Syst Neurosci 2014; 8: 58.
[PMID: 24795575]
[19]
Breteler MM, van Duijn CM, Chandra V, et al. EURODEM Risk Factors Research Group. Medical history and the risk of Alzheimer’s disease: a collaborative re-analysis of case-control studies. Int J Epidemiol 1991; 20( Suppl. 2): S36-42.
[http://dx.doi.org/10.1093/ije/20.Supplement_2.S36] [PMID: 1833352]
[20]
Breteler MM, de Groot RR, van Romunde LK, Hofman A. Risk of dementia in patients with Parkinson’s disease, epilepsy, and severe head trauma: a register-based follow-up study. Am J Epidemiol 1995; 142(12): 1300-5.
[http://dx.doi.org/10.1093/oxfordjournals.aje.a117597] [PMID: 7503050]
[21]
Cook M, Baker N, Lanes S, Bullock R, Wentworth C, Arrighi HM. Incidence of stroke and seizure in Alzheimer’s disease dementia. Age Ageing 2015; 44(4): 695-9.
[http://dx.doi.org/10.1093/ageing/afv061] [PMID: 26008894]
[22]
Bergantin LB, Caricati-Neto A. Challenges for the pharmacological treatment of neurological and psychiatric disorders: Implications of the Ca(2+)/cAMP intracellular signalling interaction. Eur J Pharmacol 2016; 788: 255-60.
[http://dx.doi.org/10.1016/j.ejphar.2016.06.034] [PMID: 27349146]
[23]
Steinlein OK. Calcium signaling and epilepsy. Cell Tissue Res 2014; 357(2): 385-93.
[http://dx.doi.org/10.1007/s00441-014-1849-1] [PMID: 24723228]
[24]
Zhang LK, Sun Y, Zeng H, et al. Calcium channel blocker amlodipine besylate therapy is associated with reduced case fatality rate of COVID-19 patients with hypertension. Cell Discov 2020; 6(1): 96.
[http://dx.doi.org/10.1038/s41421-020-00235-0] [PMID: 33349633]
[25]
D’Elia JA, Weinrauch LA. Calcium ion channels: roles in infection and sepsis mechanisms of calcium channel blocker benefits in immunocompromised patients at risk for infection. Int J Mol Sci 2018; 19(9): 2465.
[http://dx.doi.org/10.3390/ijms19092465] [PMID: 30134544]
[26]
Bergantin LB. Common issues among asthma, epilepsy, and schizophrenia: from inflammation to Ca2+/cAMP signalling. Antiinflamm Antiallergy Agents Med Chem 2020. Epub ahead of print
[http://dx.doi.org/10.2174/1871523019999201110192029] [PMID: 33176668]
[27]
Bergantin LB. A link among schizophrenia, diabetes, and asthma: Role of Ca2+/cAMP signaling. Brain Circ 2020; 6(3): 145-51.
[http://dx.doi.org/10.4103/bc.bc_66_19] [PMID: 33210037]
[28]
Bergantin LB. Diabetes and cancer: Debating the link through Ca2+/cAMP signalling. Cancer Lett 2019; 448: 128-31.
[http://dx.doi.org/10.1016/j.canlet.2019.02.017] [PMID: 30771427]
[29]
Bergantin LB. The interplay among epilepsy, parkinson’s disease and inflammation: revisiting the link through Ca2+/cAMP signalling. Curr Neurovasc Res 2021; 18(1): 162-8.
[http://dx.doi.org/10.2174/1567202618666210603123345] [PMID: 34082680]
[30]
To KK, Sridhar S, Chiu KH, et al. Lessons learned 1 year after SARS-CoV-2 emergence leading to COVID-19 pandemic. Emerg Microbes Infect 2021; 10(1): 507-35.
[http://dx.doi.org/10.1080/22221751.2021.1898291] [PMID: 33666147]
[31]
Olivier M. Modulation of host cell intracellular Ca2+. Parasitol Today 1996; 12(4): 145-50.
[http://dx.doi.org/10.1016/0169-4758(96)10006-5] [PMID: 15275223]
[32]
Scherbik SV, Brinton MA. Virus-induced Ca2+ influx extends survival of west nile virus-infected cells. J Virol 2010; 84(17): 8721-31.
[http://dx.doi.org/10.1128/JVI.00144-10] [PMID: 20538858]
[33]
Dionicio CL, Peña F, Constantino-Jonapa LA, et al. Dengue virus induced changes in Ca2+ homeostasis in human hepatic cells that favor the viral replicative cycle. Virus Res 2018; 245: 17-28.
[http://dx.doi.org/10.1016/j.virusres.2017.11.029] [PMID: 29269104]
[34]
Nugent KM, Shanley JD. Verapamil inhibits influenza A virus replication. Arch Virol 1984; 81(1-2): 163-70.
[http://dx.doi.org/10.1007/BF01309305] [PMID: 6743023]
[35]
Johansen LM, DeWald LE, Shoemaker CJ, et al. A screen of approved drugs and molecular probes identifies therapeutics with anti-Ebola virus activity. Sci Transl Med 2015; 7(290): 290ra89.
[http://dx.doi.org/10.1126/scitranslmed.aaa5597] [PMID: 26041706]
[36]
Asadi-Pooya AA. Seizures associated with coronavirus infections. Seizure 2020; 79: 49-52.
[http://dx.doi.org/10.1016/j.seizure.2020.05.005] [PMID: 32416567]
[37]
Asadi-Pooya AA, Attar A, Moghadami M, Karimzadeh I. Management of COVID-19 in people with epilepsy: drug considerations. Neurol Sci 2020; 41(8): 2005-11.
[http://dx.doi.org/10.1007/s10072-020-04549-5] [PMID: 32594268]
[38]
Bergantin LB. Diabetes and inflammatory diseases: An overview from the perspective of Ca2+/3′-5′-cyclic adenosine monophosphate signaling. World J Diabetes 2021; 12(6): 767-79.
[http://dx.doi.org/10.4239/wjd.v12.i6.767] [PMID: 34168726]

Rights & Permissions Print Cite
Article Metrics
32
1
© 2024 Bentham Science Publishers | Privacy Policy